Q-omics provides the consensus-scored BCHE profile across patient tissues and cancer cell-line models. BCHE expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BCHE is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, BCHE protein abundance shows 21,886 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BLCA, COAD, and BRCA as cancer lineages where BCHE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCHE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCHE survival associations across molecular data types. BCHE RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCHE RNA expression–survival associations across cancer types. High BCHE expression shows unfavorable associations in BLCA, HNSC, UCEC and STAD, but favorable associations in UVM and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for BCHE RNA expression.
This table summarizes BCHE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BCHE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCHE shows lower tumor expression in COAD, BLCA, LUAD, KIRC and UCEC and higher tumor expression in HNSC. The COAD box plot shows higher BCHE RNA expression in normal versus tumor tissue (log2 FC = −2.676, t-test p < 0.001).
This table shows molecular features associated with BCHE in patient tissues and cancer cell lines. In patient samples, BCHE shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, BCHE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
